Long-term effects of latanoprost monotherapy on intraocular pressure in Japanese glaucoma patients

Journal of Glaucoma

Volumn 17, Issue 8, 2008, Pages 662-666

  Kashiwagi, Kenji ^a   Tsumura, Toyoaki ^a   Tsukahara, Shigeo ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

Glaucoma; Intraocular pressure; Japanese; Latanoprost

Indexed keywords

LATANOPROST; ANTIHYPERTENSIVE AGENT; PROSTAGLANDIN F;

ADULT; AGED; ARTICLE; BLEPHARITIS; CORNEA DISEASE; DRUG EFFECT; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FILTERING OPERATION; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; JAPANESE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NORMAL TENSION GLAUCOMA; OCULAR PRURITUS; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; ASIAN; ETHNOLOGY; FOLLOW UP; JAPAN; OCULOPLETHYSMOGRAPHY; PHYSIOLOGY; VISUAL FIELD;

AGED; ANTIHYPERTENSIVE AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOLLOW-UP STUDIES; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; JAPAN; MALE; PROSTAGLANDINS F, SYNTHETIC; RETROSPECTIVE STUDIES; TONOMETRY, OCULAR; VISUAL FIELDS;

EID: 60749086034     PISSN: 10570829     EISSN: None     Source Type: Journal    
DOI: 10.1097/IJG.0b013e318166656d     Document Type: Article

References (21)

1. Hylton C, Robin AL. Update on prostaglandin analogs. Curr Opin Ophthalmol. 2003;14:65-69.
2. Susanna R Jr, Chew P, Kitazawa Y. Current status of prostaglandin therapy: latanoprost and unoprostone. Surv Ophthalmol. 2002;47: S97-S104.
3. Stjernschantz JW. From PGF (2alpha)-isopropyl ester to latanoprost: a review of the development of xalatan: the Proctor Lecture. Invest Ophthalmol Vis Sci. 2001;42:1134-1145.
4. Hejkal TW, Camras CB. Prostaglandin analogs in the treatment of glaucoma. Semin Ophthalmol. 1999;14:114-123.
5. Boger WPr. Shortterm "escape" and longterm "drift." The dissipation effects of the beta adrenergic blocking agents. Surv Ophthalmol. 1983;28:235-242.
6. Steinert RF, Thomas JV, Boger WP III. Long-term drift and continued efficacy after multiyear timolol therapy. Arch Ophthalmol. 1981;99:100-103.
7. Alm A, Widengard I. Latanoprost: experience of 2-year treatment in Scandinavia. Acta Ophthalmol Scand. 2000;78:71-76.
8. Hedman K, Watson PG, Alm A. The effect of latanoprost on intraocular pressure during 2 years of treatment. Surv Ophthalmol. 2002;47:S65-S76.
9. Ang A, Reddy MA, Shepstone L, et al. Long term effect of latanoprost on intraocular pressure in normal tension glaucoma. Br J Ophthalmol. 2004;88:630-634.
10. Group L-IIPS. Incidence of a latanoprost-induced increase in iris pigmentation in Japanese eyes. Jpn J Ophthalmol. 2006;50: 96-99.
11. Chiba T, Kashiwagi K, Ishijima K, et al. A prospective study of iridial pigmentation and eyelash changes due to ophthalmic treatment with latanoprost. Jpn J Ophthalmol. 2004;48: 141-147.
12. Chou SY, Chou CK, Kuang TM, et al. Incidence and severity of iris pigmentation on latanoprost-treated glaucoma eyes. Eye. 2005;19: 784-787.
13. Sugimoto M, Uji Y. Quantitative analysis of eyelash lengthening following topical latanoprost therapy. Can J Ophthalmol. 2002;37: 342-345.
14. Stecchi G, Saccucci S, Molinari S, et al. Eyelash hypertrichosis induced by topical latanoprost: 6-month follow-up study. Acta Ophthalmol Scand Suppl. 2002;236:56-57.
15. Tokunaga T, Kashiwagi K, Saito J, et al. A case of cystoid macular edema associated with latanoprost ophthalmic solution. Jpn J Ophthalmol. 2002;49:134-136.
16. Arcieri ES, Santana A, Rocha FN, et al. Blood-aqueous barrier changes after the use of prostaglandin analogues in patients with pseudophakia and aphakia: a 6-month randomized trial. Arch Ophthalmol. 2005;123:186-192.
17. Ogawa I, Imai K. Long-term effects of latanoprost on visual fields in eyes with normal-tension glaucoma-five-year follow-up-. Folia Ophthalmol Jpn. 2005;56:342-348.
18. Tomita G, Araie M, Kitazawa Y, et al. A three-year prospective, randomized and open comparison between latanoprost and timolol in Japanese normal-tension glaucoma patients. Eye. 2004;18:984-989.
19. Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol. 1998;126:498-505.
20. Alm A, Camras CB, Watson PG. Phase III latanoprost studies in Scandinavia, the United Kingdom and the United States. Surv Ophthalmol. 1997;41:S105-S110.
21. Camras CB, Hedman K. Rate of response to latanoprost or timolol in patients with ocular hypertension or glaucoma. J Glaucoma. 2003; 12:466-469.